18β-Glycyrrhetinic Acid

18β-Glycyrrhetinic Acid Basic information
Product Name:18β-Glycyrrhetinic Acid
Synonyms:Enoxolone, 3β-Hydroxy-11-oxo-18β,20β-olean-12-en-29-oic acid;Aloe Vera, Freeze Dried Powder;18-β-Glycyrrhetinic acid, 98+%;18-beta-glycyrrheticacid;Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3b,20b)-;(20S)-3β-Hydroxy-11-oxo-5α-olean-12-en-29-oic acid;GLYCYRRHETINIC ACID, 18B-(P);Glycyrrhetinic acid ,98%
CAS:471-53-4
MF:C30H46O4
MW:470.69
EINECS:207-444-6
Product Categories:Inhibitors;Chiral Reagents;Cosmetic Ingredients & Chemicals;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Pentacyclic Triterpenes;Tri-Terpenoids;Miscellaneous;Biochemistry;Terpenes;Terpenes (Others);Natural Plant Extract;471-53-4
Mol File:471-53-4.mol
18β-Glycyrrhetinic Acid Structure
18β-Glycyrrhetinic Acid Chemical Properties
Melting point 292-295 °C(lit.)
alpha 165 º (c=1, CHCl3,on dry ba)
Boiling point 492.11°C (rough estimate)
density 0.9967 (rough estimate)
vapor pressure 10-220Pa at 20-50℃
refractive index 162 ° (C=1, MeOH)
storage temp. 2-8°C
solubility Practically insoluble in water, soluble in ethanol, sparingly soluble in methylene chloride.
pkapKa 5.56±0.1 (Uncertain)
form Crystalline Powder
color White to off-white
optical activity[α]22/D +170.0°, c = 1 in chloroform
Water Solubility SOLUBLE IN ACETIC ACID
Merck 14,3590
BRN 2229654
LogP4.5 at 20℃
CAS DataBase Reference471-53-4(CAS DataBase Reference)
EPA Substance Registry SystemEnoxolone (471-53-4)
Safety Information
Hazard Codes Xn
Risk Statements 22-36
Safety Statements 22-24/25
WGK Germany 3
RTECS RK0180000
HS Code 29189900
Toxicitymouse,LD50,intraperitoneal,308mg/kg (308mg/kg),Drugs in Japan Vol. -, Pg. 319, 1990.
MSDS Information
ProviderLanguage
18-beta-Glycyrrhetinic acid English
SigmaAldrich English
ACROS English
18β-Glycyrrhetinic Acid Usage And Synthesis
DescriptionExtracting from liquorice (Glycyrrhiza uralensis Fisch, Gan Cao), glycyrrhetic acid also can be detected in other plants, such as Abrus cantoniensis Hance and Herba Abri fruticulosi. As one of traditional Chinese medicines, liquorice has been applied clinically for a long period. Due to its extensive usage, it plays an extremely important role in traditional Chinese medicine formula mainly as “guide” drug. As is recorded in Shen Nong’s Herbal Classic and later in pharmaceutical monographs, liquorice is able to strengthen bones and muscles and enhance metabolism and detoxification. Also, abnormal symptoms of the body and wound can be improved. Glycyrrhetic acid, the most important and potent ingredient of liquorice, has been recorded in Pharmacopoeia of the People’s Republic of China.
Description18β-Glycyrrhetinic acid is a major metabolite of glycyrrhizin , one of the main constituents of licorice. Both 18β-glycyrrhetinic acid and glycyrrhizin have been shown to exhibit anti-ulcerative, anti-inflammatory, and immunomodulatory properties. 18β-Glycyrrhetinic acid is an inhibitor of the complement pathway (IC50 = 35 μM). At 100 mg/kg/day, 18β-glycyrrhetinic acid is protective against diabetes complications by reducing lipid peroxidation and increasing antioxidant activity in diabetic rats. 18β-Glycyrrhetinic acid inhibits mammalian DNA polymerases α, γ, κ, and λ with IC50 values of 16.1, 19.3, 15.8, and 13.7 μM, respectively. At 100-200 μM, 18β-glycyrrhetinic acid suppresses LPS-induced TNF-α production and NF-κB activation in mouse macrophages.
Chemical Propertieswhite or greyish-white crystalline powder
Physical propertiesSolubility: insoluble in water; it exists in crystal with methanol and chloroform. Melting point: the compound melts at 292–295?°C. Specific optical rotation: under the condition of 20?°C, 589.3?nm, and 1?dm, polarized light rotates at 68° when it passes through the chloroform with a concentration of 64? mol/L.? Both 18α-glycyrrhetic acid and 18β-glycyrrhetic acid are chiral isomers of glycyrrhetic acid.
HistoryGlycyrrhetic acid originates from hydrolysis of glycyrrhizin, which has a therapeutic effect on disease. Dating back to the 1930s, the chemical structure of glycyrrhetic acid was demonstrated . Subsequently, the discovery of antiulcer activity promotes following research . The ramification of glycyrrhetic acid, carbenoxolone sodium, has a therapeutic effect on ulcer. In 2010, followed by the approval of raw materials, batches of tablets and capsules were approved in 2009, respectively. In foreign countries, 18β-glycyrrhetic acid was studied for anti-inflammatory effect on arthritis, rheumatoid disease, and periodontitis in BioNetWorks. The company applied for the patent of 18β-glycyrrhetic acid in 1999. Also, after joining the leading worldwide market in 2006, phase III clinical trials would be carried out in 2007. However, the progress was hindered in 2008. To detecting more indications, its carbenoxolone sodium was studied by other three companies: after conducting phase III clinical trials in the UK, the project of RB intending to improve nonspecific inflammatory bowel disease was given up in 1992. York Pharma expected to make progress in psoriasis with gel or cream; however, the project has been in a standstill after phase II clinical trials was conducted from 2005 to 2009. Canada pharmaceutical company, Oxalys Pharmaceuticals, research it for treating Huntington’s disease, and it was included in the orphan drug list by the USA in 2014. Till now, phase I clinical trials are still continuing.
UsesThe product may be used as a starting material to prepare 18β-glycyrrhetinic acid derivatives, which show anti-inflammatory and antioxidant properties.
UsesAn anti-inflammatory (topical).
Usesantitussive, antiinflammatory, antibacterial
UsesThe aglycone of the triterpenoid Glyccyrrhizic acid.
Usesglycyrrhetinic acid is anti-irritant, anti-allergenic, anti-inflammatory, skin-lightening, and smoothing properties are attributed to this ingredient, which is also a carrier. It is the organic compound derived from glycyrrhizic acid or shredded licorice roots.
DefinitionChEBI: A pentacyclic triterpenoid that is olean-12-ene substituted by a hydroxy group at position 3, an oxo group at position 11 and a carboxy group at position 30.
IndicationsTreatment of Addison’s disease, deoxycorticosterone
General Description18β-Glycyrrhetinic acid is a pentacyclic triterpenoid found in the Glycyrrhiza glabra L.(liquorice) roots. It is the key metabolite of glycyrrhizin and glycyrrhizic acid.
PharmacologyThirty percent of glycyrrhetinic acid can be effectively used by the body; both 18α-glycyrrhetic acid and 18β-glycyrrhetic acid reduce by half in 2.24 h and 11.5 h separately. CYP3A promotes metabolism with hydroxyl added to 22α and 24α .There are lots of pharmacological activities : it plays an anti-inflammatory role by inhibiting the activity of phospholipase A2 and lipoxygenase to reduce mediators of inflammation; the compound promotes antiulcer activity through the production of more PGE2 and secretion of gastric mucus; it also provokes proliferation of gastric cell to protect the mucosa from ulceration. The complex which consists of glycyrrhetinic acid and carotenoid plays antioxidation by scavenging free radical. Glycyrrhetinic acid inhibits the replication of viral DNA to achieve an antiviral effect at the concentration of 4×10?5 mol/L; it also inhibits proliferation of tumor cell and promotes apoptosis and differentiation. The decreasing ability of invasion exerts an antitumor effect. Glycyrrhetinic acid is considered to have extensive antiarrhythmic effects through inhibition of L-type calcium channel. In addition, glycyrrhetinic acid functions as an anticholinesterase (1.7×10?5 mol/L), anticoagulant, and antitetanus toxin; it also improves inner ear hearing (100 mg/kg, intramuscular injection) and improves absorption of insulin.
Anticancer ResearchGlycyrrhetinic acid in combinationwith etoposide inhibits thetopoisomerase 2α and inducesapoptosis
Cai et al.(2017)
Anticancer ResearchIt was reported that GA at noncytotoxic concentrationshowed synergistic effect in combination with anticancer drug, etoposide (VP-16).Specifically, GA enhanced cytotoxicity through regulating topoisomerase II-αtargeted by etoposide. Also, GA sensitized the cells to etoposide through elevatingtopoisomerase II-α with a 2.4-fold rate at 12 h time point. From 12 to 48 h, GAhalved the expression of topoisomerase II-α and stimulated apoptosis, whichexhibited its antineoplastic effect. They reported that GA was more potentiallyeliminating the TNBC cells when compared with Glycyrrhizin Acid (Cai et al. 2017).
Clinical UseGlycyrrhetic acid has not been applied in clinical treatment till now. Meanwhile, the ramification has come into the market for the property of antiulcer. However, with large doses and long-term usage, the drug gives rise to hypertension, sodium retention, and hypokalemia. When renin-angiotensin-aldosterone system fails to function properly, liquorice-induced pseudoaldosteronism threatens human health .
18β-Glycyrrhetinic Acid Preparation Products And Raw materials
Raw materialsEthanol-->Sucrose-->Glycyrrhizic acid-->DGL-->SIS
Preparation ProductsStearyl glycyrrhetinate
Glycyrrhizic acid Monopotassium glycyrrhizate Hyaluronic acid Roxolonium metilsulfate Ethyl 2-(Chlorosulfonyl)acetate Ascoric Acid Diammonium glycyrrhizinate Cicloxolone licorice acid Stearyl glycyrrhetinate Folic acid DGL ENOXOLONE POTASSIUM SALT Dipotassium glycyrrhizinate 18β-Glycyrrhetinic Acid Ammonium Glycyrrhizinate CHLOROPHOSPHONAZO III Citric acid

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.